ticlopidine has been researched along with Kidney Failure in 22 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 5.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
| "Our results show that renal failure history and clopidogrel and GPIIb/IIIa receptor antagonist use are independent risk factors for in-hospital bleeding in patients with acute coronary syndrome." | 3.78 | [Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization]. ( Chen, YD; Jin, ZN; Liu, H; Liu, X; Lü, SZ; Song, XT, 2012) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days." | 3.74 | Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008) |
| "Combination antiplatelet agents, particularly aspirin and ticlopidine, have found increased use in the prevention of arterial thrombosis." | 3.70 | A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. ( Fiore, L; Hasbargen, JA; Kaufman, JS; O'Connor, TZ; Perdriset, G, 2000) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 1.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| " We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
| "Treatment with ticlopidine progressively decreased sensitivity to adenosine diphosphate-induced platelet aggregation." | 1.30 | Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. ( Berglund, U; Buur, T; Donat, F; Larsson, R; Tronquet, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Verdoia, M | 1 |
| Nardin, M | 1 |
| Gioscia, R | 1 |
| Suryapranata, H | 1 |
| Kedhi, E | 1 |
| Rognoni, A | 1 |
| DE Luca, G | 1 |
| Sabouret, P | 1 |
| Taiel-Sartral, M | 1 |
| Serebruany, VL | 1 |
| Tomek, A | 1 |
| Pokov, AN | 1 |
| Kim, MH | 1 |
| Baber, U | 1 |
| Mehran, R | 1 |
| Giustino, G | 1 |
| Cohen, DJ | 1 |
| Henry, TD | 1 |
| Sartori, S | 1 |
| Ariti, C | 1 |
| Litherland, C | 1 |
| Dangas, G | 1 |
| Gibson, CM | 1 |
| Krucoff, MW | 1 |
| Moliterno, DJ | 1 |
| Kirtane, AJ | 1 |
| Stone, GW | 1 |
| Colombo, A | 1 |
| Chieffo, A | 1 |
| Kini, AS | 1 |
| Witzenbichler, B | 1 |
| Weisz, G | 1 |
| Steg, PG | 1 |
| Pocock, S | 1 |
| Zakarija, A | 1 |
| Kwaan, HC | 1 |
| Moake, JL | 1 |
| Bandarenko, N | 1 |
| Pandey, DK | 1 |
| McKoy, JM | 1 |
| Yarnold, PR | 1 |
| Raisch, DW | 1 |
| Winters, JL | 1 |
| Raife, TJ | 1 |
| Cursio, JF | 1 |
| Luu, TH | 1 |
| Richey, EA | 1 |
| Fisher, MJ | 1 |
| Ortel, TL | 1 |
| Tallman, MS | 1 |
| Zheng, XL | 1 |
| Matsumoto, M | 1 |
| Fujimura, Y | 1 |
| Bennett, CL | 1 |
| Motovska, Z | 1 |
| Widimsky, P | 1 |
| Petr, R | 1 |
| Bilkova, D | 1 |
| Marinov, I | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Coppola, A | 1 |
| De Simone, C | 1 |
| Di Capua, M | 1 |
| Tufano, A | 1 |
| Cimino, E | 1 |
| Conca, P | 1 |
| Guida, A | 1 |
| Morisco, C | 1 |
| Di Minno, G | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Ferreira-González, I | 1 |
| Marsal, JR | 1 |
| Ribera, A | 1 |
| Permanyer-Miralda, G | 1 |
| García-Del Blanco, B | 1 |
| Martí, G | 1 |
| Cascant, P | 1 |
| Martín-Yuste, V | 1 |
| Brugaletta, S | 1 |
| Sabaté, M | 2 |
| Alfonso, F | 2 |
| Capote, ML | 1 |
| De La Torre, JM | 1 |
| Ruíz-Lera, M | 1 |
| Sanmiguel, D | 1 |
| Cárdenas, M | 1 |
| Pujol, B | 1 |
| Baz, JA | 1 |
| Iñiguez, A | 1 |
| Trillo, R | 1 |
| González-Béjar, O | 1 |
| Casanova, J | 1 |
| Sánchez-Gila, J | 1 |
| García-Dorado, D | 1 |
| Yan, BP | 1 |
| Ajani, AE | 1 |
| Clark, DJ | 1 |
| Duffy, SJ | 1 |
| Andrianopoulos, N | 1 |
| Brennan, AL | 1 |
| Loane, P | 1 |
| Reid, CM | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Muller, C | 1 |
| Caillard, S | 1 |
| Jesel, L | 1 |
| El Ghannudi, S | 1 |
| Ohlmann, P | 2 |
| Sauleau, E | 1 |
| Hannedouche, T | 1 |
| Gachet, C | 1 |
| Moulin, B | 1 |
| Morel, O | 1 |
| Liu, X | 1 |
| Chen, YD | 1 |
| Lü, SZ | 1 |
| Jin, ZN | 1 |
| Liu, H | 1 |
| Song, XT | 1 |
| Kuchulakanti, PK | 1 |
| Chu, WW | 1 |
| Torguson, R | 1 |
| Rha, SW | 1 |
| Clavijo, LC | 1 |
| Kim, SW | 1 |
| Bui, A | 1 |
| Gevorkian, N | 1 |
| Xue, Z | 1 |
| Smith, K | 1 |
| Fournadjieva, J | 1 |
| Suddath, WO | 1 |
| Satler, LF | 1 |
| Pichard, AD | 1 |
| Kent, KM | 1 |
| Waksman, R | 1 |
| Münzel, TF | 1 |
| Post, F | 1 |
| Cherfan, A | 1 |
| Arabi, Y | 1 |
| Al Askar, A | 1 |
| Al Shimemeri, A | 1 |
| Marzocchi, A | 1 |
| Saia, F | 1 |
| Piovaccari, G | 1 |
| Manari, A | 1 |
| Aurier, E | 1 |
| Benassi, A | 1 |
| Cremonesi, A | 1 |
| Percoco, G | 1 |
| Varani, E | 1 |
| Magnavacchi, P | 1 |
| Guastaroba, P | 1 |
| Grilli, R | 1 |
| Maresta, A | 1 |
| Angiolillo, DJ | 1 |
| Bernardo, E | 1 |
| Jimenez-Quevedo, P | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Hernández-Antolin, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Bañuelos, C | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Pinkau, T | 1 |
| Ndrepepa, G | 1 |
| Kastrati, A | 1 |
| Mann, JF | 1 |
| Schulz, S | 1 |
| Mehilli, J | 1 |
| Schömig, A | 1 |
| Buur, T | 1 |
| Larsson, R | 1 |
| Berglund, U | 1 |
| Donat, F | 1 |
| Tronquet, C | 1 |
| Kaufman, JS | 1 |
| Fiore, L | 1 |
| Hasbargen, JA | 1 |
| O'Connor, TZ | 1 |
| Perdriset, G | 1 |
| Horwich, TB | 1 |
| Fonarow, GC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ticlopidine and Kidney Failure
| Article | Year |
|---|---|
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; | 2014 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness | 2015 |
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Topics: ADAM Proteins; ADAMTS13 Protein; Adverse Drug Reaction Reporting Systems; Animals; Autoantibodies; C | 2009 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complic | 2006 |
Prevention of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2002 |
2 trials available for ticlopidine and Kidney Failure
| Article | Year |
|---|---|
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2010 |
15 other studies available for ticlopidine and Kidney Failure
| Article | Year |
|---|---|
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous | 2023 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coagulants; Comorbidity; Coronary Angiography; | 2010 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Association of estimated GFR with platelet inhibition in patients treated with clopidogrel.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Clopidogrel; Cohort Studies; Dose-Response Relationsh | 2012 |
[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization].
Topics: Acute Coronary Syndrome; Age of Onset; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Human | 2012 |
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
Topics: Aged; Angiography; Case-Control Studies; Clopidogrel; Drug Delivery Systems; Female; Follow-Up Studi | 2006 |
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embo | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function.
Topics: Adult; Aged; Area Under Curve; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Age | 1997 |
A pharmacodynamic study of clopidogrel in chronic hemodialysis patients.
Topics: Adenosine Diphosphate; Arterial Occlusive Diseases; Chronic Disease; Clopidogrel; Dose-Response Rela | 2000 |